271980.KS

Jeil Pharmaceutical Co.,Ltd [271980.KS] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

271980.KS Stock Summary

Top 10 Correlated ETFs

271980.KS


Top 10 Correlated Stocks

271980.KS


In the News

271980.KS Financial details

Company Rating
Neutral
Market Cap
246.26B
Income
5B
Revenue
726.39B
Book val./share
10882.2
Cash/share
2447.07
Dividend
50
Dividend %
0.29%
Employees
973
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
82.03
Forward P/E
-
PEG
-6.15
P/S
0.35
P/B
1.52
P/C
6.82
P/FCF
-6.86
Quick Ratio
0.62
Current Ratio
1.01
Debt / Equity
0.54
LT Debt / Equity
0.03
-
-
EPS (TTM)
343.33
EPS next Y
-
EPS next Q
-
EPS this Y
-133.36%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
1.59%
Revenue Q/Q
1.39%
EPS Q/Q
-45.58%
-
-
-
-
SMA20
0.33%
SMA50
-1.02%
SMA100
11.13%
Inst Own
-
Inst Trans
-
ROA
1%
ROE
2%
ROC
0.03%
Gross Margin
25%
Oper. Margin
1%
Profit Margin
-
Payout
-
Shs Outstand
14.57M
Shs Float
14.44M
-
-
-
-
Target Price
-
52W Range
14540.0-22800.0
52W High
-26.75%
52W Low
+14.86%
RSI
48
Rel Volume
0.8
Avg Volume
11.3K
Volume
9.01K
Perf Week
-1.24%
Perf Month
-0.24%
Perf Quarter
3.66%
Perf Half Y
2.2%
-
-
-
-
Beta
1.145
-
-
Volatility
114.61%, 190.22%
Prev Close
-0.6%
Price
16700
Change
-1.42%

271980.KS Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric History 2019-12-312020-12-312021-12-312022-12-31 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
45.77K47.3K47.97K49.54K49.85K
Net income per share
-721.53473.24-1.03K-1.03K343.46
Operating cash flow per share
1.97K-1.3K1.31K-1.04K-341.81
Free cash flow per share
1.88K-1.5K938.51-2.2K-998.97
Cash per share
921.63450.791.92K2.17K2.45K
Book value per share
11.59K11.8K11.52K10.83K10.88K
Tangible book value per share
11.3K11.52K11.2K10.03K9.89K
Share holders equity per share
11.59K11.8K11.52K10.83K10.88K
Interest debt per share
2.29K3.45K2.9K3.66K6.24K
Market cap
531.04B914.87B494.4B324.36B258.21B
Enterprise value
549.95B960.28B508.79B343.26B310.18B
P/E ratio
-50.17132.28-32.99-21.6151.59
Price to sales ratio
0.791.320.710.450.36
POCF ratio
18.34-48.0325.88-21.41-51.84
PFCF ratio
19.27-41.7536.07-10.1-17.74
P/B Ratio
3.125.312.942.051.63
PTB ratio
3.125.312.942.051.63
EV to sales
0.821.390.730.480.43
Enterprise value over EBITDA
63.4741.55145.5-72.8316.63
EV to operating cash flow
18.99-50.4226.64-22.66-62.28
EV to free cash flow
19.95-43.8237.12-10.69-21.31
Earnings yield
-0.020.01-0.03-0.050.02
Free cash flow yield
0.05-0.020.03-0.1-0.06
Debt to equity
0.190.290.240.320.54
Debt to assets
0.080.120.090.110.17
Net debt to EBITDA
2.181.964.12-4.012.79
Current ratio
1.271.271.281.091
Interest coverage
0.8712.04-2.87-4.431.47
Income quality
-2.74-2.73-1.271.01-1
Dividend Yield
00000
Payout ratio
-0.080.15-0.07-0.060.15
Sales general and administrative to revenue
0.040.030.040.040.05
Research and developement to revenue
0.030.040.060.060.06
Intangibles to total assets
0.010.010.010.020.03
Capex to operating cash flow
-0.050.15-0.281.121.92
Capex to revenue
00-0.01-0.02-0.01
Capex to depreciation
-0.18-0.32-0.59-1.91-0.98
Stock based compensation to revenue
00000
Graham number
13.72K11.21K16.31K15.84K9.17K
ROIC
0.060.03-0.03-0.070.14
Return on tangible assets
-0.030.02-0.04-0.030.01
Graham Net
-3.7K-3.97K-4.67K-7.06K-7.9K
Working capital
55.61B59.45B62.73B22.98B-1.12B
Tangible asset value
165.72B168.38B163.58B146.22B144.15B
Net current asset value
32.59B40.33B25.53B-9.65B-13.25B
Invested capital
0.190.290.240.320.54
Average receivables
172.19B159.82B153.16B152.68B161.3B
Average payables
147.16B146.47B148.22B152.36B147.99B
Average inventory
86.26B96.69B105.88B100.8B104.46B
Days sales outstanding
88.2583.0677.6179.0383.53
Days payables outstanding
105.197.88102.5897.8997.1
Days of inventory on hand
59.0774.6368.656473.84
Receivables turnover
4.144.394.74.624.37
Payables turnover
3.473.733.563.733.76
Inventory turnover
6.184.895.325.74.94
ROE
-0.060.04-0.09-0.10.03
Capex per share
-95.15-196.17-369.21-1.16K-657.16

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric History 2022-12-312023-03-312023-06-302023-09-30 2023-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
11.77K13.12K12.3K12.16K12.33K
Net income per share
-288.18872-93-282.14-153.53
Operating cash flow per share
-533.43-741.25582.22-1.14K958.96
Free cash flow per share
-712.26-965.74447.3-1.26K785.94
Cash per share
2.17K1.76K3.14K2.5K2.45K
Book value per share
10.84K11.66K11.61K11.28K10.88K
Tangible book value per share
10.03K10.9K10.77K10.36K9.89K
Share holders equity per share
10.84K11.66K11.61K11.28K10.88K
Interest debt per share
3.53K4.11K5.16K5.78K5.93K
Market cap
324.22B269.78B272.95B239.26B258.21B
Enterprise value
343.12B302.85B309.93B294.8B310.18B
P/E ratio
-19.35.31-50.56-14.55-28.85
Price to sales ratio
1.891.411.531.351.44
POCF ratio
-41.71-24.9832.31-14.4118.48
PFCF ratio
-31.24-19.1842.05-12.9822.55
P/B Ratio
2.051.591.621.461.63
PTB ratio
2.051.591.621.461.63
EV to sales
21.591.741.661.73
Enterprise value over EBITDA
-130.3316.24545.35-601.45277.43
EV to operating cash flow
-44.14-28.0536.69-17.7522.2
EV to free cash flow
-33.06-21.5347.75-15.9927.08
Earnings yield
-0.010.050-0.02-0.01
Free cash flow yield
-0.03-0.050.02-0.080.04
Debt to equity
0.320.340.430.50.54
Debt to assets
0.110.120.150.160.17
Net debt to EBITDA
-7.181.7765.07-113.3146.49
Current ratio
1.091.131.031.011
Interest coverage
-4.7511.64-2.06-1.62-1.02
Income quality
1.85-0.74-4.823.59-6.25
Dividend Yield
00000
Payout ratio
00-0.5400
Sales general and administrative to revenue
0.050.040.050.050.05
Research and developement to revenue
0.050.050.070.060.07
Intangibles to total assets
0.020.020.020.030.03
Capex to operating cash flow
0.340.3-0.230.11-0.18
Capex to revenue
-0.02-0.02-0.01-0.01-0.01
Capex to depreciation
-1.13-1.4-0.8-0.77-0.97
Stock based compensation to revenue
00000
Graham number
8.38K15.13K4.93K8.46K6.13K
ROIC
-0.020.07-0.02-0.010
Return on tangible assets
-0.010.030-0.010
Graham Net
-7.06K-6.95K-6.86K-7.67K-7.9K
Working capital
22.98B36.47B8.33B4.81B-1.12B
Tangible asset value
146.22B158.84B156.29B150.94B144.15B
Net current asset value
-9.65B4.03B2.11B-988.64M-13.25B
Invested capital
0.320.340.430.50.54
Average receivables
158.35B164.11B164.52B164.93B169.46B
Average payables
155.03B152.57B149.69B152.21B151.44B
Average inventory
100.19B107.6B115.88B120.85B117.88B
Days sales outstanding
82.0980.9679.2687.783.27
Days payables outstanding
101.31103.8696.01104.1895.79
Days of inventory on hand
66.2478.5276.1682.7972.85
Receivables turnover
1.11.111.141.031.08
Payables turnover
0.890.870.940.860.94
Inventory turnover
1.361.151.181.091.24
ROE
-0.030.07-0.01-0.03-0.01
Capex per share
-178.83-224.49-134.91-125.37-173.02

271980.KS Frequently Asked Questions

What is Jeil Pharmaceutical Co.,Ltd stock symbol ?

Jeil Pharmaceutical Co.,Ltd is a KR stock and trading under the symbol 271980.KS

What is Jeil Pharmaceutical Co.,Ltd stock quote today ?

Jeil Pharmaceutical Co.,Ltd stock price is $16700 today.

Is Jeil Pharmaceutical Co.,Ltd stock public?

Yes, Jeil Pharmaceutical Co.,Ltd is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap